Liquid pharmaceutical composition containing piroxicam and hyaluronic acid for the treatment of osteoarthritis

A technology of hyaluronic acid and piroxicam, which is applied in the direction of drug combination, medical preparations containing active ingredients, drug delivery, etc., and can solve problems such as different and unsuitable osteoarthritis treatment effects

Inactive Publication Date: 2016-04-06
DONG A ST CO LTD
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, the mechanism is also different from actual osteoarthritis, therefore, this is not suitable for evaluating the therapeutic effect of NSAID and hyaluronic acid combined administration on osteoarthritis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liquid pharmaceutical composition containing piroxicam and hyaluronic acid for the treatment of osteoarthritis
  • Liquid pharmaceutical composition containing piroxicam and hyaluronic acid for the treatment of osteoarthritis
  • Liquid pharmaceutical composition containing piroxicam and hyaluronic acid for the treatment of osteoarthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] The present invention contains the preparation of the liquid composition of piroxicam and hyaluronic acid

[0030] Add 5.58 g of piroxicam potassium and an appropriate amount of solubilizer to about 350 ml of phosphate buffer (pH 7.4), then stir at 30° C. for 1 hour to dissolve the mixture, and then add phosphate buffer to a final volume of 500 ml. After sterilization with a syringe filter, 5.0 g of sodium hyaluronate was then added. The composition was then prepared as a final step with stirring at a temperature of 30-40° C. for 12 hours using an overhead mixer.

Embodiment 2 and 3

[0031] preparation of the liquid composition containing piroxicam and hyaluronic acid of the present invention

[0032] A liquid composition containing piroxicam and hyaluronic acid was prepared using the same method as in Example 1 above, but the contents were as shown in Table 1 below, and they were referred to as Example 2 and Example 3, respectively.

experiment example 1

[0042] Anti-inflammatory efficacy evaluation in Mono-iodoacetate-induced osteoarthritis model

[0043] For this evaluation, 8-week-old male SD rats purchased from Daehan Biolink Co., Ltd. were stabilized for four weeks in a clean area (animal breeding room on the second basement floor of the new building of the research institute), wherein the temperature in the clean area was maintained at 23 ±2°C, relative humidity maintained at 40-60%, ventilation frequency maintained at more than 10 times / hour, ammonia concentration maintained at or below 20ppm, average illuminance at 150-300lux, and noise level maintained at or below 60 loudness units (phon), and the light and dark cycle was maintained at 12 hours. At the beginning of the experiment, Mono-iodoacetate (hereinafter referred to as MIA) was administered into the right joint cavity at 3mg / 30ul / only. One day after the administration, the joint diameters of the rats were measured, and they were divided into groups so that each...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the pharmaceutical composition for the treatment of osteoarthritis comprising piroxicam or pharmaceutically acceptable salt thereof and hyaluronic acid or pharmaceutically acceptable salt thereof at a specific ratio that generates synergistic effect on both anti-inflammatory and analgesic effects simultaneously. The present invention provides a pharmaceutical composition for the treatment of osteoarthritis comprising 0.25-10.0 wt% of piroxicam or its pharmaceutically acceptable salt and 0.5-5.0 wt% of hyaluronic acid or its pharmaceutically acceptable salt, where the weight ratio between piroxicam or its pharmaceutically acceptable salt and hyaluronic acid or its pharmaceutically acceptable salt is between 1:1 and 1:3. The liquid pharmaceutical composition according to the present invention has an outstanding therapeutic effect simultaneously on both inflammation and pain, thus providing an injectable formulation for intra-articular injection with synergistic effect on the treatment of osteoarthritis.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating osteoarthritis (degenerative arthritis) containing piroxicam and hyaluronic acid in a specific ratio. The pharmaceutical composition can exhibit synergistic effects at the same time with anti-inflammatory and analgesic effects . Background technique [0002] Osteoarthritis, known as degenerative arthritis, is a disease that causes severe pain, joint movement disturbances, and other symptoms due to structural changes in the joints and damage to the articular cartilage (DiDomenica et al., 2005 ). Because the physiologic state of osteoarthritis (including the extent of cartilage loss and bone changes) is assessed radiographically, it is difficult to clearly define osteoarthritis (Ayral et al., 2005), however, it is generally defined as " A state characterized by loss of the bursa, joint, and periarticular bone" (Altman 1987; Altman et al., 1990). Evaluation of the knee joints of actual ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/54A61K31/728A61P19/02A61P19/00
CPCA61K31/5415A61K9/0019A61K47/02A61K31/728A61P19/00A61P19/02A61P43/00A61K2300/00A61K31/54
Inventor 金舜会孙美苑张善瑀朴赞雄马炅完郑详蒝
Owner DONG A ST CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap